AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: LYRA
Report Date: 2026-07-15
Full Report: https://amaly.io/stock/LYRA

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: Lyra Therapeutics, Inc. (LYRA) is a clinical-stage biotechnology company developing anti-inflammatory therapies for chronic rhinosinusitis. While its core business activities are Shariah-compliant, the financial screening reveals significant non-compliance due to an exceptionally high interest income ratio of 192.44%, exceeding all standard thresholds. Debt and liquidity ratios are compliant, and no non-permissible business activities were identified. Index inclusion research confirms exclusion from all major Shariah indices. Overall, the company is classified as non-compliant, with a B quality rating reflecting strong business permissibility but critical financial concerns.

Primary Compliance Concerns:
- Interest Income Ratio: 192.44% (threshold: 5%)

Purification Requirement: 192.44%
Index Inclusion: Not included in any major Shariah indices (S&P, MSCI, FTSE, DJIM)

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 21.8%
Liquidity Ratio: 20.7%
Interest Income Ratio: 192.4%
Purification Required: 0.00%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-12-31

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-03-01T00:00:00Z

---
Full interactive report: https://amaly.io/stock/LYRA
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.